Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broking boss makes £2.6m profit

Mon, 02nd Nov 2009 16:30

Evolution chief executive Alex Snow has sold £5.2m of shares after being awarded 4.59m shares from two company option schemes after the vesting conditions for the shares were met. The Evolution Group Plc 2000 Executive Share Option Scheme issued 3.09m shares to Snow, Of these, 2.026m did not have any performance criteria, while the award of the rest was based on share price performance. These shares were acquired at 58.67p a share. The total cost was £1.81m. The other 1.5m shares were issued under the Evolution Group Plc 2001 Executive Share Option Scheme - following the achievement of share price performance criteria - and they cost 52.3p each. The total cost was £785,000. That means that Snow made a £2.6m profit on the share sales, which were at 163p a share. The share price is the highest it has been for more than three years. He retains 1.4m of the shares that he was awarded. This still leaves Snow with a higher percentage of the company. He owns 5.6m shares, which is equivalent to 2.42% of Evolution. Snow has taken up all the shares he had under option at the time of the 2008 annual report. Last week, the broker announced that its 2009 profits would be better than expected. Corporate activity has increased in the second half of the year. Funds under management have grown to £5bn at the end of September 2009. In April, Snow raised nearly £927,000 by selling shares at 114p each. That followed the exercise of options over 2m shares at 1p each - a total cost of £20,000. Snow said that the sale proceeds paid for the options and associated tax costs. That means that Snow has made more than £3.5m profit from share sales this year, while retaining 2.57m shares he has been awarded. Top Director BuysAccess Intelligence (ACC) Director name: Mr David LoweAmount purchased: 961,111 @ 4.70p Value: £45,172CLS Holdings (CLI) Director name: Mr Sten A MortstedtAmount purchased: 7,940 @ 443.00p Value: £35,174Jetion Solar Holdings (JHL) Director name: Mr Raymond WongAmount purchased: 30,000 @ 64.50p Value: £19,350Top Director SellsEvolution Group (EVG) Director name: Mr Alex SnowAmount sold: 3,191,565 @ 163.00p Value: £5,202,251Diageo (DGE) Director name: Mr Paul S WalshAmount sold: 99,000 @ 1,000.00p Value: £990,000
More News
13 Oct 2022 17:55

CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits

(Correcting Harmony Energy Income Trust's use of funds.)

Read more
12 Oct 2022 21:46

TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
12 Oct 2022 12:23

Evgen starts recruiting volunteers for trial of lead asset

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.

Read more
10 Oct 2022 12:10

LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry

(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.

Read more
10 Oct 2022 11:00

AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
10 Oct 2022 09:58

Evgen Pharma shares jump 65% as licences SFX-01 composition for autism

(Alliance News) - Evgen Pharma PLC on Monday said it has signed a licencing deal for up to USD160.5 million with Stalicla SA for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.

Read more
14 Jul 2022 16:39

UK shareholder meetings calendar - next 7 days

Friday 15 July 
Aveva Group PLCAGM
DCC PLCAGM
DP Poland PLCAGM
Griffin Mining LtdAGM
MC Mining PLCGM re subscription
Monday 18 July 
Audioboom Group PLCAGM
JPMorgan European Discovery Trust PLCAGM
Tuesday 19 July 
Biotech Growth Trust PLCAGM
Clean Power Hydrogen PLCAGM
e-Therapeutics PLCAGM
Norcros PLCAGM
Ten Lifestyle Group PLCGE re commitment to sustainability, B Corp certification
Wednesday 20 July 
ADM Energy PLC AGM
Alkemy Capital Investments PLCAGM
DeepVerge PLCAGM
easyJet PLCGM re purchase of 56 Airbus A320neo family aircraft & conversion of 18 A320neo family aircraft
Fidelity China Special Situations PLCAGM
HarbourVest Global Private Equity LtdAGM
HICL Infrastructure PLCAGM
Novacyt SAAGM r
Plaza Centers NVAGM
Premier Foods PLCAGM
Royal Mail PLCAGM
Triad Group PLCAGM
Wynnstay Properties PLCAGM & GM re share buyback
Thursday 21 July  
Big Yellow Group PLCAGM
Evgen Pharma PLCAGM
Experian PLCAGM
Halma PLCAGM
Intermediate Capital Group PLCAGM
Johnson Matthey PLCAGM
Octopus AIM VCT PLCAGM
Pennon Group PLCAGM
Pires Investments PLCGM re offer from Tern PLC
QinetiQ Group PLCAGM
SSE PLCAGM
Tern PLCGM re offer for Pires Investments PLC
Vp PLCAGM
Workspace Group PLCAGM
Zephyr Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
13 Jun 2022 19:22

IN BRIEF: Evgen to work with University of Michigan on asset SFX-01

Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.

Read more
8 Jun 2022 14:26

Evgen Pharma starts trial to test breast cancer tablet; loss narrows

(Alliance News) - Evgen Pharma PLC on Wednesday said it would begin a trial to test a new medicinal product later this year and said its results for the most recent financial year are in line with expectations.

Read more
25 May 2022 22:02

TRADING UPDATES: Tekcapital fundraise; Kromek wins US government order

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
18 Jan 2022 11:48

Evgen agrees fresh licensing deal with Spanish institutions

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.

Read more
18 Jan 2022 11:32

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Read more
7 Dec 2021 21:49

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

Read more
30 Nov 2021 16:26

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
10 Nov 2021 18:22

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.